Valuation: IntoCell, Inc.

Market Cap 244B 182M 157M 148M 135M 252M 17.35B 254M 1.77B 682M 8.83B 682M 667M 28.08B P/E 2024 *
-
P/E 2025 -77.1x
Enterprise Value 224B 166M 144M 136M 123M 231M 15.89B 233M 1.62B 624M 8.08B 624M 611M 25.71B EV / Sales 2024 *
-
EV / Sales 2025 365,559,272x
Free-Float
78.73%
Yield 2024 *
-
Yield 2025 -
1 day-3.56%
1 week-10.90%
Current month-14.19%
1 month-25.37%
3 months-27.20%
6 months-66.21%
Current year-71.66%
1 week 16,130
Extreme 16130
18,100
1 month 16,130
Extreme 16130
22,925
Current year 13,050
Extreme 13050
63,500
1 year 13,050
Extreme 13050
74,900
3 years 13,050
Extreme 13050
74,900
5 years 13,050
Extreme 13050
74,900
10 years 13,050
Extreme 13050
74,900
Manager TitleAgeSince
Chief Executive Officer 66 2015-03-31
Director of Finance/CFO 69 2019-05-31
Chief Tech/Sci/R&D Officer 58 2021-03-31
Director TitleAgeSince
Director/Board Member 66 2015-03-31
Director/Board Member 58 2021-03-31
Director/Board Member 65 2021-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/25 Buy

Founder

10,000 0.0674%
7/15/25 Buy

Founder

26,000 0.1751%
5/28/25 Free 40,400 --
Change 5-day change 1-year change 3-year change Capi.($)
-3.56%-10.90%-57.85% - 189M
+0.56%-5.82%-2.45%+9.99% 45.48B
+0.66%-2.34%+340.62%+524.38% 43.68B
+1.49%-0.78%+41.90%+22.65% 43.09B
+2.11%-1.24%+9.09%+76.85% 39.4B
+0.34%-4.94%+9.34%+40.23% 31.91B
+0.53%-2.08% - - 17.31B
+1.34%+0.70%+21.35%+111.39% 16.4B
+2.07%-0.77%+13.07%+32.89% 14.24B
-1.85%-5.33%+78.63%+34.13% 13.28B
Average +0.37%-3.39%+50.41%+106.56% 26.5B
Weighted average by Cap. +0.94%-3.26%+75.90%+126.85%

Financials

2024 2025
Net sales 2.91K 2.16 1.87 1.76 1.6 3 206.18 3.02 21.05 8.11 104.91 8.11 7.92 333.76 2.3K 1.71 1.48 1.4 1.27 2.37 163.18 2.39 16.66 6.41 83.03 6.41 6.27 264.15
Net income -9.91B -7.37M -6.37M -6.02M -5.46M -10.23M -704M -10.31M -71.83M -27.66M -358M -27.66M -27.04M -1.14B -10.6B -7.88M -6.82M -6.44M -5.84M -10.94M -753M -11.03M -76.83M -29.58M -383M -29.58M -28.93M -1.22B
Net Debt -2.15B -1.59M -1.38M -1.3M -1.18M -2.21M -152M -2.23M -15.55M -5.99M -77.49M -5.99M -5.85M -247M -20.59B -15.3M -13.24M -12.5M -11.34M -21.24M -1.46B -21.41M -149M -57.44M -743M -57.44M -56.16M -2.37B
Logo IntoCell, Inc.
IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.
Employees
-
Date Price Change Volume
26-09-14 ₩16,270.00 -3.56% 31,190
26-09-11 ₩16,870.00 -0.65% 21,644
26-09-10 ₩16,980.00 -1.34% 31,277
26-09-09 ₩17,210.00 -1.77% 25,257
26-09-08 ₩17,520.00 +0.98% 39,029

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A287840 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!